Loading cancer entity…
Loading cancer entity…
Clinical trials
10,627 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,641)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04541368 | A Study of CS1-targeted CAR-T Cells Therapy for Relapsed Multiple Myeloma After BCMA CAR-T Cells Therapy | not yet recruiting | Early Phase 1 | 50 | Zhejiang UniversityOTHER | 1 | Dec 10, 2020 | clinicaltrials |
| NCT04440436 | Assessment of Safety and Efficacy of IM19 for Recurrent or Refractory (R/R) Non-Hodgkin's Lymphoma(NHL) Patients | recruiting | Phase 1 / Phase 2 | 52 | Beijing Immunochina Medical Science & Technology Co., Ltd.INDUSTRY | 1 | Dec 8, 2020 |
| clinicaltrials |
| NCT04603872 | CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological Malignancies | recruiting | Early Phase 1 | 120 | Zhejiang UniversityOTHER | 1 | Oct 28, 2020 | clinicaltrials |
| NCT04532203 | A Study of CAR-T Cells Therapy for Patients With Relapsed and/or Refractory Central Nervous System Hematological Malignancies | recruiting | Early Phase 1 | 72 | Zhejiang UniversityOTHER | 1 | Oct 26, 2020 | clinicaltrials |
| NCT02657785 | Treatment of PCNSL With R-IDARAM and Intrathecal Immunochemotherapy | recruiting | Phase 2 / Phase 3 | 100 | Navy General Hospital, BeijingOTHER | 1 | Sep 9, 2020 | clinicaltrials |
| NCT02836158 | Therapeutic Effects of R-IDARAM and Intrathecal Immunochemotherapy on Elderly Patients With PCNSL | recruiting | Phase 2 / Phase 3 | 100 | Navy General Hospital, BeijingOTHER | 1 | Sep 9, 2020 | clinicaltrials |
| NCT04520529 | Identification of Prognostic Factors and New Therapeutic Targets in Cutaneous Lymphomas(LYMPHOTEQ) | not yet recruiting | N/A | 500 | Assistance Publique - Hôpitaux de ParisOTHER | 0 | Aug 20, 2020 | clinicaltrials |
| NCT04491721 | Follow-up the OS and PFS of Rituximab Biosimilar HLX01 and MabThera, in Untreated Subjects With CD20+ DLBCL | enrolling by invitation | — | 407 | Chinese Academy of Medical SciencesOTHER | 1 | Jul 29, 2020 | clinicaltrials |
| NCT04338386 | Detection and Pathogenesis of Novel Protein F | not yet recruiting | — | 100 | Wuhan Asia Heart HospitalOTHER | 0 | Apr 10, 2020 | clinicaltrials |
| NCT03815279 | A Nationwide Phase 2 Trial of Patients With Smoldering and Active Multiple Myeloma (MM)(iStopMM) | enrolling by invitation | Phase 2 | 80 | Landspitali University HospitalOTHER | 1 | Aug 16, 2019 | clinicaltrials |
| NCT04025450 | Comparation of Chidamide Plus VRD (Bortezomib, Lenalidomide, Dexamethasone) With VRD Regimen for Primary High-Risk Multiple Myeloma Patients | recruiting | Phase 1 / Phase 2 | 50 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Jul 19, 2019 | clinicaltrials |
| NCT03966443 | Fluciclovine PET/CT in Multiple Myeloma Patients(FLUCIPET) | recruiting | — | 10 | Oslo University HospitalOTHER | 1 | May 30, 2019 | clinicaltrials |
| NCT03196414 | Study of T Cells Targeting CD138/BCMA/CD19/More Antigens (CART-138/BCMA/19/More) for Chemotherapy Refractory and Relapsed Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 10 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | May 2, 2019 | clinicaltrials |
| NCT03647072 | PPI Versus Histamine Antagnists as Adjuvant to Chemotherapy | recruiting | Phase 3 | 60 | Sherief Abd-ElsalamOTHER | 1 | Aug 27, 2018 | clinicaltrials |
| NCT03562169 | The Role of Ixazomib in Autologous Stem Cell Transplant in Relapsed Myeloma - Myeloma XII (ACCoRd) | recruiting | Phase 3 | 406 | University of LeedsOTHER | 1 | Jun 19, 2018 | clinicaltrials |
| NCT03494296 | A Prospective Study of Low-dose Decitabine Combined With COP Regimen in the Treatment of Relapsed and Refractory DLBCL | recruiting | — | 150 | First Affiliated Hospital of Harbin Medical UniversityOTHER | 1 | Apr 11, 2018 | clinicaltrials |
| NCT03313271 | China Lymphoma Patient Registry Study(CLAP) | recruiting | — | 5,000 | Jun ZhuOTHER | 1 | Oct 18, 2017 | clinicaltrials |
| NCT03199066 | Non-Hodgkin Lymphoma - Observational Epidemiological and Clinical Study (NiHiL) | recruiting | — | 20,000 | Czech Lymphoma Study GroupOTHER | 1 | Jun 26, 2017 | clinicaltrials |
| NCT02869542 | Institut Paoli Calmettes Lymphoma Database | recruiting | — | 16,000 | Institut Paoli-CalmettesOTHER | 1 | Aug 17, 2016 | clinicaltrials |
| NCT02869555 | Institut Paoli Calmettes Multiple Myeloma Database | recruiting | — | 5,000 | Institut Paoli-CalmettesOTHER | 1 | Aug 17, 2016 | clinicaltrials |
| NCT02259556 | CD30-directed Chimeric Antigen Receptor T (CART30) Therapy in Relapsed and Refractory CD30 Positive Lymphomas(CART30) | recruiting | Phase 1 / Phase 2 | 30 | Chinese PLA General HospitalOTHER | 1 | Jan 28, 2016 | clinicaltrials |
| NCT02497898 | Treatment of CIK for Patients With Refractory Non-Hodgkin Lymphoma | not yet recruiting | Phase 2 | 1,000 | The First People's Hospital of ChangzhouOTHER | 0 | Jul 15, 2015 | clinicaltrials |
Data updated 22 days agoSource updated Dec 10, 2020source: clinicaltrials